BioOrbit, founded in 2023, is a UK-based start-up and space manufacturing company aiming to develop pharmaceutical factories in space. They are focused on leveraging microgravity for the large-scale crystallization of protein drugs, particularly for cancer immunotherapy, with the goal of enabling subcutaneous injection and improving patient access to treatments. BioOrbit is currently developing hardware for efficient protein drug crystallization and aims to partner with pharmaceutical companies and researchers, and has a scheduled launch with The Exploration Company for Q2 2025. The company has also received funding from 7percent Ventures.
All verified mentions of this organization in source documents.
BioOrbit is developing space-drug manufacturing capabilities to reformulate drugs for self-administration by patients.
Molly Mulligan was appointed president of BioOrbit.
BioOrbit built BOX, a microwave-sized autonomous manufacturing unit that can fly to space and produce crystallized cancer drugs inside a reentry vehicle or commercial space station.
BioOrbit sent its first BOX to space aboard The Exploration Company’s Nyx spacecraft last year.
BioOrbit plans to open an office on the East Coast of the United States.
BioOrbit expects to fly as many as two missions in 2027.
BioOrbit expects the regulatory process to take about five years before clinical trials can begin.
Ken Savin was appointed chief science officer of BioOrbit.
BioOrbit’s primary targets are anti-cancer antibodies.
BioOrbit’s seed round included participation from Auxxo, Seedcamp, Type One Ventures, 7percent Ventures, and undisclosed angel investors.
BioOrbit is scheduled to send its second mission to orbit this year.
BioOrbit raised £9.8 million (€11.4 million) in seed funding.
LocalGlobe and BREEGA co-led BioOrbit’s £9.8 million (€11.4 million) seed round.
BioOrbit hired two former Redwire veterans to help it pursue contracts with large pharmaceutical firms.
BioOrbit positions PHARM’s objective of enabling space-manufactured drugs to meet the same regulatory standards as Earth-produced drugs as a world first.
BioOrbit Ltd received £250,000 for the PHARM study to design an end-to-end mission to manufacture drugs in microgravity.
BioOrbit is working with relevant regulators so medicines produced in space can be approved under the same regulatory framework as Earth-manufactured drugs.
BioOrbit is working with relevant regulatory bodies to enable commercialisation of drugs manufactured in microgravity.
BioOrbit Ltd received a £250,000 (≈$341,000) contract for the PHARM study to design an end-to-end mission to manufacture drugs in microgravity.
On February 9, 2026, the UK Space Agency awarded research contracts to BioOrbit, Space Forge, and OrbiSky to advance technology demonstration and commercialization of advanced materials manufacturing in low Earth orbit.